United States: Pharmaceutical Life Cycle Management: Navigating The New IP, FDA, And Antitrust Terrain

Efforts to extend the life cycle of pharmaceutical products frequently involve innovations and improvements in product design, formulation, route of administration and treatment indications. In addition, negotiation of agreements with competitors, including generic and biosimilar manufacturers, is frequently employed as part of a life cycle management strategy. However, recent changes in patent, regulatory and antitrust laws have introduced greater complexity and higher risk into these strategies.

On October 23, 2015, a distinguished panel of BakerHostetler partners led an exclusive seminar in person and online at which they discussed these and related issues and provided suggestions for developing successful life cycle management strategies. Carl W. Hittinger, Lee Rosebush, Lance Shea and Maurice Valla are all deeply knowledgeable attorneys with decades of experience in helping clients meet their pharmaceutical business objectives.

Patent-Based Exclusivity

Maurice Valla discussed several broad categories with regard to patent-based exclusivity:

  • Early-stage development
  • Developmental candidate identification
  • Clinical development
  • Approaching approval
  • Prior to launch and follow-on indications
  • Active pharmaceutical ingredient characteristics and new formulations
  • Additional protection strategies

Selected highlights:

Early-stage development: Patent practitioners have historically focused on obtaining protection for therapeutic targets such as isolated DNA sequences, or for research tools used to identify compounds that interact with those isolated DNA sequences. But Valla also explained that patent practitioners now face a legal landscape in which isolated sequences are no longer patentable unless the sequence has a markedly different characteristic from its naturally occurring counterpart.

He also discussed how patent practitioners regularly sought patent protection for correlations between a therapeutic target and disease. For example, a claim might be directed to a method of treating a disease by interacting with a particular target. The current § 112 jurisprudence forecloses these types of claims unless the specification provides sufficient examples of the therapeutic compound to inform one of ordinary skill in the art. Valla suggested that such target/disease correlation claims might still be allowable when the target is well-characterized and the contemplated method of treatment is the administration of a biologic such as an antibody or an oligonucleotide. Unlike small molecule therapeutics, the prevailing view is that one of skill in the art could design an antibody or an interfering RNA to a sufficiently definite target.

Developmental candidate identification: Valla said that freedom to operate should be a consideration from the very beginning of the patenting process. He advised looking at what already exists in the patent landscape in terms of the therapeutic target, drugs and competing companies. If patents exist, ask whether those patents are still valid under the latest legal standards and how much of the patent term remains.

Valla explained that the primary concern from a legal standpoint is how broadly to draft a claim. In the past, practitioners drafted broad generic claims to cover a vast universe of species. Valla noted that the current practice involves starting with a broad generic claim then narrowing the scope of the claim. If the field is very crowded, it may be desirable to claim a narrower genus, especially where that narrow genus has unexpected advantages over the prior art.

He cautioned that many countries require the applicant to limit the scope of the claims to only those compounds that have actually been synthesized. This is a significant shift from the conception-focused practice in the United States. In certain countries, like China, Japan and Taiwan, it is necessary to submit data for a representative number of compounds that shows that the compounds actually work for their claimed purpose. Such requirements are in direct tension with the "first to file" system in the United States and elsewhere. Determining when to file may come down to a business decision where the applicant balances timing considerations with the importance of capturing the international markets.

Clinical development: Valla said that it is desirable to claim as broadly as possible from the outset to anticipate future changes to the product. He advised that in a situation where protection is later sought for a particular salt form of the compound, such claims may face obstacles where the compound is already known and there are a limited number of pharmaceutically acceptable salts. Similarly, it may be difficult to get a claim directed to a particular isomer where the racemic mixture is known in the art.

Approaching approval: 35 U.S.C. § 156 provides for an extension to the patent term to compensate for any delay introduced by the regulatory approval process. Valla advised that the applicant should carefully consider which patent to extend as it is only possible to extend the term for one patent per product. He suggested considering which patent is strongest in terms of validity and which patent will give the longest period of exclusivity if extended. He also noted that the extension does not apply to the patent as a whole, but only to the product for which approval was sought. Interpreting what qualifies as the same product becomes particularly difficult when dealing with biologics, where the marketed product is similar, but not identical, to the claimed product.

Prior to launch and follow-on indications: Valla stressed the importance of reassessing the intellectual property landscape and the client's portfolio throughout the approval process, as the transition to commercial-scale manufacturing might yield methods of treating additional conditions. However, diagnostic-style claims may face greater scrutiny under some newly developed case law. Valla suggested looking for novel testing methods or reagents, or simply drafting the claims as a method of treatment. Method of treatment claims are valuable to the drug manufacturer insofar as they provide support for a product label, but they may be less valuable to third parties given the complexities of distributed infringement.

Active pharmaceutical ingredient characteristics and new formulations: Valla said that it might also be possible to claim new formulations. For example, the applicant may wish to draft claims covering new coatings or new routes of administration, keeping in mind that the new formulation must overcome an obviousness challenge or problems stemming from a lack of written description in the specification.

Additional protection strategies: In addition to drug/drug combinations, the applicant may pursue drug/device combinations such as a loaded syringe or inhaler. Such a combination would be separately patentable and listable in the Orange Book, and could provide an attractive avenue for gaining protection for an old drug.

Conclusion

Valla concluded with the observation that the applicant also may wish to seek patent coverage for an approved Risk Evaluation and Mitigation Strategy (REMS), though courts are increasingly viewing these sorts of patents as directed to the abstract idea of a method of distributing or controlling the risk in a population.

FDA Exclusivity

Five Types of Exclusivities

In addition to the patent rights that a drug sponsor should use to protect its products in the increasingly competitive pharmaceutical marketplace, there are powerful regulatory exclusivities that should be considered. Understanding the different exclusivities and the pathways to obtain them will help shape a pharmaceutical company's research and development strategy and enhance its competitive advantage.

Rosebush discussed five types of Food and Drug Administration (FDA) exclusivities available for pharmaceutical products:

  • New chemical entity (NCE) exclusivity
  • New clinical investigation (NCI) exclusivity
  • Orphan drug exclusivity
  • Pediatric exclusivity
  • Biologics license application (BLA)

Each exclusivity has specific criteria that an applicant/sponsor must meet. In addition, each exclusivity has its own limitations on what competitive activities are excluded.

New chemical entity exclusivity (NCE): A sponsor may apply for NCE exclusivity for "a drug that contains no active moiety that has been approved by FDA in any other application submitted under section 505(b) of the act." The active moiety of a drug is the molecule or ion responsible for the physiological or pharmacological action of the drug.

NCE exclusivity can be obtained by submitting either a 505(b)(1) or 505(b)(2) application. A 505(b)(1) applicant will submit to the FDA safety and efficacy data generated in clinical trials performed by the applicant to support its request for exclusivity. A 505(b)(2) applicant relies at least partially on prior clinical data that the sponsor did not generate.

NCE exclusivity typically lasts five years and prevents the submission of any 505(b)(2) or abbreviated new drug applications (ANDAs) for drugs containing the same active moiety.

New clinical investigation exclusivity (NCI): NCI exclusivity can be granted to applicants submitting 505(b)(1), 505(b)(2), or supplemental applications. The sponsor must perform clinical studies, which the FDA defines as "an investigation in humans, the results of which (1) have not been previously relied upon by FDA to demonstrate substantial evidence of effectiveness of a previously approved drug product for any indication or of safety in a new patient population and (2) do not duplicate the results of another investigation relied upon by FDA to demonstrate a previously approved drug's effectiveness or safety in a new patient population."

NCI exclusivity prohibits the FDA from approving a 505(b)(2) or ANDA application for three years, but it does not prevent applicants from submitting their applications. NCI exclusivity is available for "recycled" or "rebranded" drugs, or those drugs deemed to have the same active moiety as previously approved drugs, provided the new product relies on a new clinical study. "Recycled" drugs can include extended-release versions of drugs currently on the market or new salt forms of the drugs. NCI exclusivity also is granted for new indications, dosage regimens, patient populations and formulations of products previously on the market.

Orphan drug exclusivity: Orphan drug designation, or drugs intended for conditions that affect fewer than 200,000 people in the United States, may be eligible for seven years of market exclusivity. Originally intended for sponsors who would be unable to recoup the costs associated with developing an orphan drug, this designation provides full market exclusivity, which means the FDA will not approve another sponsor's marketing application for the same drug with the same indication for seven years from the date of the orphan product's approval letter from the FDA.

Rosebush noted that receiving an orphan drug designation does not limit the sponsor to the orphan indication. While the drug will enjoy the market exclusivity for the orphan indication, the sponsor also may pursue a more broadly applicable indication. He gave the example of Viagra, a well-known treatment for erectile dysfunction (ED), which was initially used to treat pediatric pulmonary hypertension, a condition affecting fewer than 200,000 people in the United States. Viagra received orphan drug designation for the pediatric pulmonary hypertension indication, while Pfizer also was able to get a broad label for ED.

Pediatric exclusivity: This is only available for a drug if the FDA requests a sponsor to undertake pediatric studies for a specific indication. But Rosebush emphasized that the sponsor can initiate contact and ask the FDA to request the pediatric studies. If a sponsor complies with the request to perform pediatric studies, the drug will likely receive the six-month pediatric exclusivity even if the drug is never approved for the pediatric indication studied by the sponsor. The six-month pediatric exclusivity period is added to any FDA exclusivity the drug enjoys, as well as the patent rights covering the drug.

Biologics license applications exclusivity (BLA): Biologics also are entitled to FDA-regulated exclusivities. Section 7002 of the Patient Protection and Affordable Care Act (PPACA) provides 12 years of exclusivity for approved BLA. BLA exclusivity is not available for supplements or subsequent applications by the same sponsor for a change that results in a new indication, dosing schedule, dosage form, delivery system, delivery device or strength. Only applications by the same sponsor for changes to an existing biologic that result in a modification of safety, purity or potency can be granted an additional 12 years of exclusivity. Biologics can also receive orphan drug and pediatric exclusivities.

Conclusion

In conclusion, Rosebush said sponsors need to be aware of the regulatory exclusivities that are available in addition to patent protection. These exclusivities are designed to encourage the development of new, safe and effective treatments. While taking advantage of these exclusivities may help a sponsor realize a return on investment, Rosebush warns that failure to utilize the regulatory exclusivities can result in increased competition and sponsors using potential research and development resources to fund expensive litigation.

To continue reading this article, please click here

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.